A Drug Interaction Study of Danicopan
- Conditions
- Healthy
- Interventions
- Registration Number
- NCT04709094
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Brief Summary
This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.
- Detailed Description
This study was conducted to assess the 2-way interaction between danicopan and warfarin (Part 1), bupropion (Part 2), and ethinyl estradiol/norethindrone (EE/NET) as an oral contraceptive (Part 3).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 52
- Parts 1 and 2: adult males or females between 18 and 55 years of age, inclusive, at screening. Part 3: adult females between 18 and 65 years of age, inclusive, at screening.
- Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive, with a minimum body weight of 50.0 kg at screening.
- No clinically significant history or presence of electrocardiogram abnormalities at screening.
- Non-sterile male participants must agree to abstinence or use a highly effective method of contraception.
- Female participants must be of non-childbearing potential and need not employ a method of contraception.
- Part 1 only: Participant has a negative fecal occult blood test at screening.
-
Clinically significant laboratory abnormalities.
-
History of any medical or psychiatric condition or disease that might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study.
-
History or presence of drug or alcohol abuse within previous 2 years, current tobacco/nicotine user, or positive for alcohol and/or drug screen at screening or Day -1 of Period 1.
-
History or presence of clinically significant seizures, head injury, or head trauma.
-
History of procedures that could alter absorption or excretion of orally administered drugs.
-
History of meningococcal infection, or a first-degree relative with a history of meningococcal infection.
-
A history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs.
-
Body temperature ≥ 38.0°Celsius at screening or prior to first dosing in Period 1 or history of febrile illness, or other evidence of infection, within 14 days prior to first dosing.
-
Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days before first dosing, or receipt of blood products within 6 months prior to first dosing.
-
Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days before first dosing, whichever is longer.
Part 1 Only:
-
History or presence of any of the following, with clinical significance:
- bleeding disorder(s), including relevant familial history;
- anemia (for example, history of temporary anemia during pregnancy is acceptable);
- thromboembolic disease;
- bleeding in the gastrointestinal tract or central nervous system.
-
Has active severe gingivitis.
-
Clinically significant illness, clinically significant surgery, including tooth extraction, trauma, or head injury, within 28 days before Day 1 of Period 1.
-
Participant is employed or actively involved in any circumstance that would place them at increased risk of hemorrhage during the study (for example, contact sports, strenuous or unaccustomed weight lifting, running, bicycling).
-
Participant has taken large daily doses of vitamin K (> 25 micrograms/daily) and/or has a diet rich in vitamin K 14 days prior to the first dosing.
Part 2 Only:
-
Any significant finding on the Columbia-suicide severity rating scale.
-
History or presence of any of the following, with clinical significance:
- bulimia or anorexia nervosa;
- hypertension;
- angle-closure glaucoma;
- seizure disorder;
- prior seizure to previous bupropion administration;
- head trauma.
Part 3 Only:
-
History or presence of:
- migraines or severe headaches;
- thrombotic disorders (thrombophlebitis, deep vein thrombosis);
- cerebrovascular accident;
- hypertension;
- transient ischemic attacks;
- undiagnosed vaginal bleeding;
- liver tumors or liver disease;
- jaundice with previous use of oral contraceptives or past pregnancy;
- diabetes (including gestational diabetes);
- carcinoma of the endometrium, breast or other known or suspected estrogen dependent neoplasia;
- family history of first degree relative with breast, ovarian, cervical, or endometrial/uterine cancer;
- history of abnormal pap smear (high-grade squamous intraepithelial lesion or greater result) including positive human papilloma virus test and/or cervical cancer, or history of cervical procedures including loop electrosurgical excision procedure or conization;
- any condition that would contraindicate the use of oral contraceptives.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 1: Danicopan and Warfarin Danicopan Period 1: Participants received a single dose of warfarin. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin. Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2. Part 3: Danicopan and EE/NET Danicopan Period 1: Participants received a single dose of EE/NET. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET. Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2. Part 3: Danicopan and EE/NET Ethinyl Estradiol/Norethindrone Period 1: Participants received a single dose of EE/NET. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET. Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2. Part 1: Danicopan and Warfarin Warfarin Period 1: Participants received a single dose of warfarin. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin. Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2. Part 2: Danicopan and Bupropion Danicopan Period 1: Participants received a single dose of bupropion. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion. Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2. Part 2: Danicopan and Bupropion Bupropion Period 1: Participants received a single dose of bupropion. Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion. Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2.
- Primary Outcome Measures
Name Time Method Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Warfarin Under Multiple Doses Of Danicopan Up to 168 hours postdose Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan Up to 168 hours postdose Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan Up to 168 hours postdose Part 2: AUC0-inf Of Single-dose Bupropion Under Multiple Doses Of Danicopan Up to 96 hours postdose Part 2: Cmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan Up to 96 hours postdose Part 2: Tmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan Up to 96 hours postdose Part 3: AUC0-inf Of Single-dose EE/NET Under Multiple Doses Of Danicopan Up to 96 hours postdose Part 3: Cmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan Up to 96 hours postdose Part 3: Tmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan Up to 96 hours postdose
- Secondary Outcome Measures
Name Time Method Part 1: International Normalized Ratio (INR) Of Single-dose Warfarin Under Multiple Doses Of Danicopan Up to 168 hours postdose Blood samples will be collected for prothrombin time/INR determination.
Part 1: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Warfarin Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration) Part 2: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Bupropion Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration) Part 3: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of EE/NET Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)
Trial Locations
- Locations (1)
Clinical Study Site
🇺🇸Tempe, Arizona, United States